›Portfolio Companies

Past, Present and Future Leaders

InterWest is proud and privileged to partner with visionary management teams who are shaping the future of Information Technology and Healthcare. The companies they have started are vital parts of the portfolio of industry-leading startups that InterWest has helped over the last four decades.

Our Companies

Early stage IT and Healthcare Investing

Healthcare

Healthcare

USDS

Mon, 06/11/2012 - 11:17 -- admin

USDS independently evaluates medical laboratory diagnostic tests to validate quality, speed development, assure alignment with regulatory requirements, guide regulatory pathway strategy, and inform reimbursement decisions. The performance, intended use, and risk assessment of diagnostic tests are certified through the company’s DxSTANDARDS process, which uses standards and methods based on the consensus of regulatory, industry, and academic experts.

Trius Therapeutics

Mon, 06/11/2012 - 11:17 -- admin

Trius Therapeutics (TSRX) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company is addressing the need for novel therapeutics to treat multi-drug-resistant bacterial infections as they become more resistant to currently marketed drugs. Trius was acquired by Cubist in 2013.

Paratek Pharmaceuticals

Mon, 06/11/2012 - 11:15 -- admin

Paratek Pharmaceuticals (PRTK) is a pharmaceuticals company focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering. Our lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern.

TESARO

Mon, 06/11/2012 - 11:15 -- admin

Tesaro (TSRO) is an oncology-focused biopharmaceutical company dedicated to
improving the lives of cancer patients by developing and providing safer
and more effective therapeutics and supportive care products. Since its
founding, Tesaro in-licensed Rolapitant from OPKO Health, as well as
small molecule inhibitors of Anaplastic Lymphoma Kinase from Amgen.
Tesaro plans to develop one or more compounds for oncology indications,
including the treatment of patients with non-small-cell lung cancer.

Sera Prognostics

Mon, 06/11/2012 - 11:12 -- admin

Sera Prognostics develops simple blood tests that predict preterm birth, preeclampsia and other pregnancy complications. Using these tests, physicians can make early and accurate assessment of pregnancy complication risks so they can effectively manage their patients’ pregnancies.

ReVision Optics

Mon, 06/11/2012 - 11:09 -- admin

ReVision Optics is focused on developing unique optical solutions for the treatment of presbyopia. Their flagship product, the Raindrop® Near Vision Corneal Inlay, is a patented inlay that is designed to gradually change the shape of the cornea to improve near vision in presbyopic patients. Raindrop Inlay is currently available in many Asian and EU countries and is actively pursuing regulatory approvals in other markets worldwide.

EpicentRx

Mon, 06/11/2012 - 11:07 -- admin

EpicentRx discovers and develops compounds sourced and adapted from the aerospace industry for treating cancer and other indications.

On Demand Therapeutics

Mon, 06/11/2012 - 11:02 -- admin

On Demand Therapeutics (ODTx) is developing implantable devices to enable on-demand release of drugs to the back of the eye, controlled by the ophthalmologist, leveraging existing equipment and skills. In addition to its own intellectual property, ODTx has acquired rights to the patent portfolio and technical expertise developed by InterWest company MicroCHIPS in the areas of implantable drug delivery and monitoring devices.

Ocera Therapeutics

Mon, 06/11/2012 - 11:01 -- admin

Ocera Therapeutics, Inc. (NASDAQ:OCRX) is a clinical stage biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver disease.

Pages

Subscribe to RSS - Healthcare
Facebook Google+ Twitter Email LinkedIn Share